ArticleOncotarget2018
Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma.ESMO open · 2026Trial
- Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.Future oncology (London, England) · 2021Trial
- Pervasive tissue specificity of driver genes revealed by mutational analysis of 265 cancer types.iScience · 2026Article
- Review
- Notch signaling regulates a metabolic switch through inhibiting PGC-1α and mitochondrial biogenesis in dedifferentiated liposarcoma.Oncogene · 2023Article
- Spatial transcriptomics reveal topological immune landscapes of Asian head and neck angiosarcoma.Communications biology · 2023Article
- Targeted Treatment of Soft-Tissue Sarcoma.Journal of personalized medicine · 2023Review
- The Landscape of Immunotherapy for Retroperitoneal Sarcoma.Current oncology (Toronto, Ont.) · 2023Review
- Dedifferentiated liposarcoma in the abdominal cavity: a case report.Clinical journal of gastroenterology · 2022Article
- The immune subtypes and landscape of sarcomas.BMC immunology · 2022Article
- Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center.International journal of cancer · 2022Article
- Pediatric liposarcoma: A case series and literature review.Pediatric blood & cancer · 2021Review
- Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma.Molecular biology reports · 2021Review
- Inhibition of P53-mediated cell cycle control as the determinant in dedifferentiated liposarcomas development.American journal of cancer research · 2021Article
- Sustained activation of notch signaling maintains tumor-initiating cells in a murine model of liposarcoma.Cancer letters · 2020Article
- What Are the Results of Resection of Localized Dedifferentiated Liposarcomas in the Extremities?Clinical orthopaedics and related research · 2020Article
- Molecular targets and novel therapeutic avenues in soft-tissue sarcoma.Current oncology (Toronto, Ont.) · 2020Review
- Identification of somatic alterations in lipoma using whole exome sequencing.Scientific reports · 2019Article
- Precision Oncology in Sarcomas: Divide and Conquer.JCO precision oncology · 2019Review
- Adrenal Liposarcoma: A Novel Presentation of Multiple Endocrine Neoplasia Type 1.AACE clinical case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
Abstract
Well-differentiated/dedifferentiated liposarcoma is a common soft tissue sarcoma with approximately 1500 new cases per year. Surgery is the mainstay of treatment but recurrences are frequent and systemic options are limited. 'Tumor genotyping' is becoming more common in clinical practice as it offers the hope of personalized targeted therapy. We wanted to evaluate the results and the clinical utility of available next-generation sequencing panels in WD/DD liposarcoma. Patients who had their tumor sequenced by either FoundationOne (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.